Showing 1 - 20 results of 31 for search '"antiretroviral drugs"', query time: 0.10s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

    Clinical testing of antiretroviral drugs as future prevention against vaginal and rectal transmission of HIV infection – a review of currently available results by Vysloužil Jakub, Kubová Kateřina, Tkadlečková Veronika Nováková, Vetchý David

    Published 2019-09-01
    “…This review summarizes the results obtained during long-term clinical testing (2005–2018) of antiretroviral drugs against vaginal and rectal transmission of HIV infection.…”
    Get full text
    Article
  6. 6

    Performance of antiretroviral drugs supply chain management and related challenges in Amhara National Regional State, Ethiopia.... by Meseret Tilahun Zeleke, Berhanemeskel Weldegerima Atsbeha, Belachew Yebeyin Melaku, Yesuneh Tefera Mekasha, Abibo Wondie Mekonen, Shimelis Dagnachew Nigatu

    Published 2025-03-01
    “…However, interruptions in access and stock outs are the major challenges in the supply chain of antiretroviral drugs. The issues are very high, particularly in developing countries like Ethiopia. …”
    Get full text
    Article
  7. 7
  8. 8

    Drugs as a cause of perforating dermatoses – a literature review by Lidia Mądrzak, Izabela Staniszewska, Arkadiusz Moskwa, Agnieszka Kalińska-Bienias

    Published 2024-11-01
    “…Perforating dermatoses can be induced by the molecularly targeted therapy drugs (sorafenib, nilotinib, dasatinib, erlotinib, gefitinib, vemurafenib, lenvatinib, sirolimus, bevacizumab, necitumumab, panitumumab, cetuximab, bendamustine-rituximab, terepril), monoclonal antibodies (infliximab, etanercept, ranibizumab, natalizumab), as well as immunomodulatory imide drugs (lenalidomide, leflunomide), antiretroviral drugs (indinavir, telaprevir) and penicillamine. …”
    Get full text
    Article
  9. 9

    Kaposi´s sarcoma, epidemic type. Case presentation by Gilberto Serrano Ocaña, Juan Carlos Ortiz Sablon, Ilen Ochoa Tamayo

    Published 2009-05-01
    “…It affects approximately 20% of people with HIV that don’t take antiretroviral drugs. It is more common in homosexual’s patients, but may appear in any HIV positive individual, in Africa where heterosexual HIV transmission route is the most important can also be found in children and women. …”
    Get full text
    Article
  10. 10

    Antiretroviral therapies and status of people living with HIV in Japan: An update from hospital survey and national database. by Yoshiyuki Yokomaku, Tatsuya Noda, Mayumi Imahashi, Yuichi Nishioka, Tomoya Myojin, Aikichi Iwamoto, Tomoaki Imamura

    Published 2025-01-01
    “…A significant transition to single-tablet regimens and newer, highly effective antiretroviral drugs was observed, optimizing treatment adherence and outcomes. …”
    Get full text
    Article
  11. 11

    Hybrid optimal control for HIV multi-drug therapies: A finite set control transcription approach by Divya Thakur, Belinda Marchand

    Published 2012-09-01
    “…In this study, the treatment of Human Immunodeficiency Virus (HIV) infection is investigated through an optimal structured treatment interruption (STI) schedule of two classes of antiretroviral drugs, mainly, reverse transcriptase inhibitors and protease inhibitors. …”
    Get full text
    Article
  12. 12

    Assessment of Antiretroviral Treatment Adherence among Children Attending Care at a Tertiary Hospital in Southeastern Nigeria by Cletus Akahara, Emeka Nwolisa, Kelechi Odinaka, Seline Okolo

    Published 2017-01-01
    “…Our aim was to assess the antiretroviral drugs adherence status of HIV-infected children attending care at a tertiary hospital in Southeastern Nigeria. …”
    Get full text
    Article
  13. 13

    Accessibility to, Acceptability of, and Adherence to HIV/AIDS Prevention Services by Men Who Have Sex with Men: Challenges Encountered at Facility Level by P. C. N. Otambo, A. Makokha, M. Karama, M. Mwangi

    Published 2016-01-01
    “…Over 70% of MSM reported that TB drugs, antiretroviral drugs, lubricants, condoms, and other STI treatment services were accessible. …”
    Get full text
    Article
  14. 14

    Characterization of the Protective HIV-1 CTL Epitopes and the Corresponding HLA Class I Alleles: A Step towards Designing CTL Based HIV-1 Vaccine by Sajib Chakraborty, Taibur Rahman, Rajib Chakravorty

    Published 2014-01-01
    “…Human immunodeficiency virus (HIV) possesses a major threat to the human life largely due to the unavailability of an efficacious vaccine and poor access to the antiretroviral drugs against this deadly virus. High mutation rate in the viral genome underlying the antigenic variability of the viral proteome is the major hindrance as far as the antibody based vaccine development is concerned. …”
    Get full text
    Article
  15. 15

    Challenges in Providing Treatment and Care for Viral Hepatitis among Individuals Co-Infected with HIV in Resource-Limited Settings by Wirach Maek-a-Nantawat, Anchalee Avihingsanon, Pirapon June Ohata

    Published 2012-01-01
    “…The options for antiretroviral drugs are limited and rely on global funds and research facilities. …”
    Get full text
    Article
  16. 16

    The Palatability of Lopinavir and Ritonavir Delivered by an Innovative Freeze-Dried Fast-Dissolving Tablet Formulation by David W. Pittman, Alexandra M. Brantly, Alexandra L. Drobonick, Hannah T. King, Daniel C. Mesta, Caroline G. Richards, Manjari Lal, Manshun Lai

    Published 2018-01-01
    “…Negative hedonic sensory qualities of HIV antiretroviral drugs often reduce patient adherence particularly in pediatric populations requiring oral consumption. …”
    Get full text
    Article
  17. 17

    Modelling the immunopathogenesis of HIV-1 infection and the effect of multidrug therapy: The role of fusion inhibitors in HAART by Gesham Magombedze, Winston Garira, Eddie Mwenje

    Published 2008-05-01
    “…In this study, we develop a new mathematical model ofthe immuno-pathogenesis of HIV-1 infection, which we use to assess virologicalresponses to both intracellular and extracellular antiretroviral drugs. We firstdevelop a basic mathematical model of the immuno-pathogenesis of HIV-1infection that incorporates three distinct stages in the infection cycle of HIV-1:entry of HIV-1 into the cytoplasm of CD4+ T cells, transcription of HIV-1RNA to DNA within CD4+ T cells, and production of HIV-1 viral particleswithin CD4+ T cells. …”
    Get full text
    Article
  18. 18

    Efficacy and safety of an Albuvirtide-based regimen for preventing mother-to-child transmission of multidrug-resistant HIV: a case report by Na Li, Shifei Wen, Fangfang Zhu, Guirong Liu, Daqing Zhu

    Published 2025-01-01
    “…Abstract Background Antiretroviral drugs are essential for preventing mother-to-child transmission (MTCT) of HIV in HIV-infected pregnant women. …”
    Get full text
    Article
  19. 19

    Prevalence and factors associated with xerostomia in patients hospitalized due AIDS-related complications by Jhonatan Yukio Naka, Adryano Arana Kamei, Vanessa C. Klamas, Mateus A. Ventura, Marcelo Morato, Rafael Z. Mobile, Antonio A. S. D. Lima

    Published 2024-10-01
    “…This fact may be associated with low salivary flow and the use of various drugs, including antiretroviral drugs.…”
    Get full text
    Article
  20. 20

    Impaired Urine Dilution Capability in HIV Stable Patients by Waldo H. Belloso, Mariana de Paz Sierra, Matilde Navarro, Marisa L. Sanchez, Ariel G. Perelsztein, Carlos G. Musso

    Published 2014-01-01
    “…Viral infection itself and the use of some antiretroviral drugs contribute to this condition. The thick ascending limb of Henle’s loop (TALH) is the tubule segment where free water clearance is generated, determining along with glomerular filtration rate the kidney’s ability to dilute urine. …”
    Get full text
    Article